# Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

> **NCT05371353** · — · RECRUITING · sponsor: **Shanghai Bovax Biotechnology Co., Ltd.** · enrollment: 600 (estimated)

## Conditions studied

- HPV Infections
- Cervical Cancer Stage IIa
- Vaginal Cancer
- Genital Wart
- CIN1
- CIN2
- CIN3

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05371353
- **Lead sponsor:** Shanghai Bovax Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-14
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2024-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05371353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05371353, "Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05371353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*